Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to firstname.lastname@example.org so that we can defer those challenges. Your health and safety are paramount to us.
Posted 14 February 2013 | By Alexander Gaffney, RAC,
A new draft decision by the UK's cost containment agency, the National Institute of health and Clinical Excellence (NICE), not to recommend reimbursement for Novartis' first-in-class new drug for blood cancer (myelofibrosis) related splenomegaly could serve as a disincentive for future research and development on therapies intended for rare diseases, critics say.
Those critics contend that if a company is unable to expect a return on the substantial investment that is needed to bring a new drug to market, then there is no incentive to undertake that investment. Similar concerns were the driving force behind the US's Orphan Drug Act of 1983, which provided sponsors of rare disease therapies market-based and research incentives aimed at incentivizing investment.
At issue in the UK is not the efficacy of the Novartis' drug, Jakavi (ruxolitinib), which NICE concedes is effective in reducing spleen size and in treating symptoms of myelofibrosis, such as itch and fatigue. NICE even believes the drug may improve survival in blood cancer patients.
But the regulator has determined that the drug is not cost-effective when compared with other available therapies-a common finding by regulators that has been the bane of many therapies before it, including those for rare diseases.
But critics say the denial of Jakavi ignored the fact that no other currently available treatment does what Jakvi does: target the underlying molecular defect that drives blood cancer. Further, they contend that denying this drug could be a powerful signal to other developers of rare diseases that investment costs aren't worth the uncertain return, denying patients of potential therapies.
In the UK, the annual incidence of myelofibrosis is estimated to be in the range of 0.34-0.76 people in every 100,000, with those over the age of sixty most at risk. Myelofibrosis is an uncommon, life-threatening blood cancer characterized by bone marrow failure, enlarged spleen (splenomegaly) and debilitating symptoms such as; extreme fatigue, night sweats and intractable pruritus (itching), poor quality of life and weight loss, as well as shortened survival.
Read all Breaking News from RegLink